Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COVID-19), requiring admission to the intensive care unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, here, we build 3 cohorts of patients categorized in COVID-19−ARDS+, COVID-19+ARDS+, and COVID-19+ARDS−, and compare, by high-dimensional mass cytometry, their immune landscape. A cell signature associating S100A9/calprotectin-producing CD169+ monocytes, plasmablasts, and Th1 cells is found in COVID-19+ARDS+, unlike COVID-19−ARDS+ patients. Moreover, this signature is essentially shared with COVID-19+ARDS− patients, suggesting that severe COVID-19 patients, whether or not they experience ARDS, display similar immune profiles. We show an increase in CD14+HLA-DRlow and CD14lowCD16+ monocytes correlating to the occurrence of adverse events during the ICU stay. We demonstrate that COVID-19-associated ARDS displays a specific immune profile and may benefit from personalized therapy in addition to standard ARDS management. Read more:
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
Recent News
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
Recent News
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
Recent News
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Recent News
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Recent News
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...
Recent News
01
/04
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
02
/04
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
03
/04
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
04
/04
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...